MetaCap

Cabaletta Bio (CABA) vs Lineage Cell Therapeutics (LCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cabaletta Bio (CABA) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 55.0% versus a loss of 55.6%. Over five years, LCTX leads with a -61.2% price change compared with -91.9% for CABA. Cabaletta Bio is the larger company by market cap ($201.9 million vs $195.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CABA-55.00%LCTX-55.64%
+107%+22%-63%
Nov 21, 20251 yearNov 20, 2026
CABA-92.19%LCTX-66.29%
+119%+7%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CABA versus LCTX key metrics
MetricCABALCTX
Share price$0.9361$0.7719
Market cap$201.94M$195.26M
1-day change-7.32%-5.87%
YTD return-57.26%-53.78%
1-year return-55.00%-55.64%
5-year return-91.93%-61.21%
EPS (TTM)$-1.33$-0.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$14.56M
Revenue growth (YoY)—+53.24%
Net income (latest FY)$-167.86M$-63.53M
Operating margin—-251.57%
Net margin—-436.47%
52-week high$4.23$1.99
52-week low$0.93$0.77
Distance from 52-week high-77.87%-61.21%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1155.21%+612.53%
Average volume5.15M1.64M
Shares outstanding215.72M252.95M
Employees15472
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

About Lineage Cell Therapeutics

LCTX stock →

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees

CABA vs LCTX FAQ

Which is bigger, Cabaletta Bio or Lineage Cell Therapeutics?

Cabaletta Bio (CABA) is larger, with a market capitalization of $201.94M compared with $195.26M for Lineage Cell Therapeutics (LCTX).

Which stock has performed better over the past year, CABA or LCTX?

CABA returned -55.00% over the past 12 months, compared with -55.64% for LCTX (price return, excluding dividends). Past performance does not predict future results.

Are Cabaletta Bio and Lineage Cell Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons